Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 14/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.40 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.39 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22541191 | 0.94 | BRD4 (0.48) | BRD4HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL15525678 | 0.92 | BRD4 (0.41) | BRD4HSP90AA1HSP90AB1 | |
| SCHEMBL30368801 | 0.92 | BRD4 (0.49) | BRD4HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL15525654 | 0.91 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1HSP90B1TRAP1PDK1 | |
| SCHEMBL16569660 | 0.91 | HSP90AA1 (0.44) | BRD4HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL22529570 | 0.89 | BRD4 (0.45) | BRD4HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL15526006 | 0.89 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1 | |
| SCHEMBL24321084 | 0.88 | BRD4 (0.45) | BRD4HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL22529571 | 0.87 | BRD4 (0.43) | BRD4HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL22547923 | 0.87 | BRD4 (0.47) | BRD4HSP90AA1HSP90AB1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3738594-A1 | TARGETED THERAPEUTICS HAVING AN HSP90 LIGAND AS BINDING MOIETY | Madrigal Pharmaceuticals, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3035938-B1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS INC (US) | 2020-08-19 | — | — | EP | disclosed |
| CN-110559446-A | Targeted therapeutics | 马德里加尔制药公司 | 2019-12-13 | — | — | CN | disclosed |
| US-9597343-B2 | Targeted therapeutics | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-21 | — | — | US | disclosed |
| EP-3129064-A2 | TARGETED THERAPEUTICS | Synta Pharmaceuticals Corp. (US) | 2017-02-15 | — | — | EP | disclosed |
| WO-2015143004-A9 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2016-09-29 | — | — | WO | disclosed |
| EP-3035938-A1 | TARGETED THERAPEUTICS | Synta Pharmaceuticals Corp. (US) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015134464-A2 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-09-11 | — | — | WO | disclosed |
| US-20150139905-A1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS, INC. | 2015-05-21 | — | — | US | disclosed |
| WO-2015038649-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-03-19 | — | — | WO | disclosed |
| EP-2838909-A2 | TARGETED THERAPEUTICS | Synta Pharmaceuticals Corp. (US) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013158644-A2 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150139905-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | BRD4 344/4885HSP90AA1 5/4885HSP90AB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.